S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
ADPT · Adaptive Biotechnologies Corporation
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Adaptive Biotechnologies Corp (ADPT)
NASDAQ NMS - GLOBAL MARKET
Life Sciences Tools & Services
$25.34
+0.91
(+3.72%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$25.34
$24.25
$25.73
52-WEEK RANGE
$25.34
$12.00
$30.74
What's happening
- ADPT is up 3.72% today, trading at $25.34. — Live quote
- Volume today (125,300) is well below its 3-month average of 2,681,480. (Finnhub fundamentals)
- Reports earnings on 2026-11-04 (after market close), 13 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.10 actual vs. $-0.14 estimated (+26.7%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 5
Buy 8
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (15 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
ADPT
+50.37%
vs S&P 500
+37.59%
1-YEAR RETURN
ADPT
+36.96%
vs S&P 500
+22.40%
6-MONTH RETURN
ADPT
+73.44%
3-MONTH RETURN
ADPT
+8.15%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.10
Est. $-0.14
BEAT +26.7%
2026-04-26 (Q1 2026)
$-0.12
Est. $-0.16
BEAT +26.5%
2026-01-26 (Q4 2025)
$-0.09
Est. $-0.18
BEAT +51.3%
2025-10-26 (Q3 2025)
$0.06
Est. $-0.15
BEAT +140.2%
Valuation Measures & Ratios
Enterprise Value4$4.09B
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)12.73
Price / Book724.02
EV4 / Revenue13.27
EV4 / EBITDA—
Profit Margin-20.73%
Operating Margin-19.86%
Return on Equity (ROE8)-32.64%
Return on Assets (ROA9)-11.88%
Avg Volume (3M)2,681,480
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $3.41B | $2.14B | $2.38B | $1.76B | $1.11B |
| P/E | -44.98 | -32.44 | -30.54 | -13.13 | -7.12 |
| Price/Sales | 11.56 | 7.75 | 9.46 | 8.74 | 6.03 |
| Price/Book | 23.89 | 9.89 | 11.65 | 9.77 | 5.82 |
| EV/Revenue | 10.99 | 7.94 | 9.77 | 9.19 | 6.48 |
| ROE | -53.10% | -30.49% | -38.15% | -74.43% | -81.74% |
| ROA | -11.85% | -13.04% | -15.90% | -26.93% | -30.47% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short11,843,887
Change from Prior Settlement-12.20%
% of Float—
Days to Cover (Short Ratio)4.43
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 21.5% on the provider's reported measure. Finnhub fundamentals ↗
- Trailing 52-week price return is +37.0%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is -20.7%. Finnhub fundamentals ↗
- Latest SEC filing is Form 4, filed 2026-10-21; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ADPT
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $71.6M | $70.9M | $94.0M | $58.9M | $52.4M | $46.4M | $43.2M | $41.9M |
| Operating income | -$15.8M | -$19.2M | $10.3M | -$25.0M | -$29.6M | -$32.6M | -$47.3M | -$48.8M |
| Net income | -$39.8M | -$20.0M | $9.5M | -$25.6M | -$29.9M | -$32.1M | -$46.2M | -$47.5M |
| EPS (diluted) | $-0.25 | $-0.13 | $0.06 | $-0.17 | $-0.20 | $-0.22 | $-0.31 | $-0.33 |
| EPS (basic) | $-0.25 | $-0.13 | $0.06 | $-0.17 | $-0.20 | $-0.22 | $-0.31 | $-0.33 |
| Operating margin | -$22 | -$27 | $11 | -$43 | -$56 | -$70 | -$110 | -$116 |
| Net margin | -$56 | -$28 | $10 | -$44 | -$57 | -$69 | -$107 | -$113 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $640.7M | $505.9M | $512.7M | $490.6M | $496.6M | $510.9M | $539.4M | $558.5M |
| Total liabilities | $490.0M | $281.7M | $287.7M | $286.4M | $317.1M | $320.6M | $336.9M | $334.9M |
| Stockholders' equity | $142.9M | $216.3M | $218.8M | $204.4M | $179.7M | $190.4M | $202.7M | $223.8M |
| Total current assets | $420.6M | $291.8M | $300.2M | $281.4M | $261.9M | $256.5M | $283.8M | $308.3M |
| Total current liabilities | $87.7M | $87.0M | $89.9M | $83.4M | $92.1M | $87.8M | $98.1M | $87.6M |
| Cash & equivalents | $169.9M | $77.6M | $70.5M | $55.0M | $43.2M | $50.6M | $47.9M | $38.1M |
| Accounts receivable | $49.5M | $48.3M | $50.4M | $44.8M | $44.3M | $43.6M | $41.7M | $40.8M |
| Inventory | $10.5M | $11.2M | $9.8M | $9.9M | $8.4M | $8.7M | $8.4M | $12.0M |
| Property, plant & equipment | $29.5M | $30.8M | $34.1M | $37.5M | $41.1M | $44.4M | $48.6M | $51.3M |
| Goodwill | $119.0M | $119.0M | $119.0M | $119.0M | $119.0M | $119.0M | $119.0M | $119.0M |
| Intangible assets | $884.0K | $1.3M | $1.7M | $2.2M | $2.6M | $3.0M | $3.4M | $3.9M |
| Other non-current assets | $1.5M | $1.2M | $1.2M | $1.8M | $2.0M | $1.9M | $2.3M | $2.6M |
| Accounts payable | $5.2M | $9.6M | $6.5M | $10.3M | $6.9M | $6.4M | $7.3M | $7.4M |
| Accrued liabilities | $10.7M | $7.5M | $7.7M | $7.2M | $7.2M | $7.8M | $8.2M | $6.1M |
| Deferred revenue (current) | $53.3M | $49.4M | $45.2M | $41.3M | $55.3M | $54.8M | $55.7M | $51.9M |
| Short-term debt | $0 | $5.8M | $4.6M | $2.4M | $3.1M | $2.0M | $865.0K | — |
| Long-term debt | $0 | $124.7M | $126.6M | $129.4M | $130.5M | $131.6M | $132.4M | $132.7M |
| Other non-current liabilities | $20.0K | $20.0K | $20.0K | $20.0K | $20.0K | $20.0K | $20.0K | $20.0K |
| Common stock & paid-in capital | $16.0K | $16.0K | $15.0K | $15.0K | $15.0K | $15.0K | $14.0K | $14.0K |
| Retained earnings | -$1.42B | -$1.38B | -$1.36B | -$1.35B | -$1.36B | -$1.33B | -$1.30B | -$1.27B |
| Accumulated other comprehensive income (loss) | -$212.0K | -$28.0K | $253.0K | $211.0K | $73.0K | $134.0K | $166.0K | $497.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.4M | -$9.5M | $2.1M | -$7.1M | -$12.4M | -$28.5M | -$12.5M | -$27.1M |
| Investing cash flow | -$43.5M | $9.1M | -$8.3M | $17.3M | $3.3M | $25.6M | $22.1M | $5.3M |
| Financing cash flow | $142.2M | $7.5M | $21.7M | $1.7M | $1.6M | $5.5M | $127.0K | $40.0K |
| Free cash flow | -$7.6M | -$10.3M | $1.4M | -$7.5M | -$13.1M | -$29.7M | -$12.6M | -$27.4M |
| Capital expenditures | $1.2M | $796.0K | $636.0K | $409.0K | $655.0K | $1.3M | $80.0K | $344.0K |
| Share-based compensation | $11.1M | $11.9M | $12.7M | $13.3M | $13.4M | $12.1M | $12.8M | $13.5M |
| Change in accounts receivable | $1.2M | -$2.0M | $5.5M | $536.0K | $702.0K | $1.9M | $899.0K | $5.2M |
| Change in inventory | -$561.0K | $1.3M | $10.0K | $1.3M | -$95.0K | -$264.0K | -$3.4M | -$1.7M |
| Purchases of investments | $82.7M | $38.9M | $46.7M | $33.2M | $51.1M | $50.7M | $44.8M | $63.3M |
| Share repurchases | $25.0M | — | — | — | $0 | — | — | — |
| Other financing activities | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $277.0M | $179.0M | $170.3M | $185.3M | $154.3M |
| Operating income | -$57.1M | -$162.5M | -$227.0M | -$200.2M | -$209.0M |
| Net income | -$59.5M | -$159.5M | -$225.2M | -$200.2M | -$207.3M |
| EPS (diluted) | $-0.39 | $-1.08 | $-1.56 | $-1.40 | $-1.48 |
| EPS (basic) | $-0.39 | $-1.08 | $-1.56 | $-1.40 | $-1.48 |
| Operating margin | -$21 | -$91 | -$133 | -$108 | -$135 |
| Net margin | -$21 | -$89 | -$132 | -$108 | -$134 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $512.7M | $539.4M | $661.1M | $856.6M | $923.3M |
| Total liabilities | $287.7M | $336.9M | $352.9M | $392.5M | $319.2M |
| Stockholders' equity | $218.8M | $202.7M | $308.4M | $464.2M | $604.0M |
| Total current assets | $300.2M | $283.8M | $410.2M | $562.1M | $402.7M |
| Total current liabilities | $89.9M | $98.1M | $88.0M | $109.8M | $113.8M |
| Cash & equivalents | $70.5M | $47.9M | $65.1M | $90.0M | $139.1M |
| Accounts receivable | $50.4M | $41.7M | $38.0M | $40.1M | $17.4M |
| Inventory | $9.8M | $8.4M | $14.4M | $14.5M | $19.3M |
| Property, plant & equipment | $34.1M | $48.6M | $68.2M | $83.4M | $85.3M |
| Goodwill | $119.0M | $119.0M | $119.0M | $119.0M | $119.0M |
| Intangible assets | $1.7M | $3.4M | $5.1M | $6.8M | $8.5M |
| Other non-current assets | $1.2M | $2.3M | $3.6M | $2.1M | $875.0K |
| Accounts payable | $6.5M | $7.3M | $7.7M | $8.1M | $3.3M |
| Accrued liabilities | $7.7M | $8.2M | $8.6M | $12.4M | $9.3M |
| Deferred revenue (current) | $45.2M | $55.7M | $48.6M | $64.1M | $80.5M |
| Short-term debt | $4.6M | $865.0K | — | — | — |
| Long-term debt | $126.6M | $132.4M | $130.7M | $125.4M | — |
| Other non-current liabilities | $20.0K | $20.0K | — | — | — |
| Common stock & paid-in capital | $15.0K | $14.0K | $14.0K | $14.0K | $14.0K |
| Retained earnings | -$1.36B | -$1.30B | -$1.14B | -$919.1M | -$718.9M |
| Accumulated other comprehensive income (loss) | $253.0K | $166.0K | $215.0K | -$4.1M | -$1.1M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$46.0M | -$95.2M | -$156.3M | -$183.9M | -$192.7M |
| Investing cash flow | $38.0M | $77.8M | $129.6M | $2.9M | $181.2M |
| Financing cash flow | $30.4M | $241.0K | $2.2M | $132.3M | $27.1M |
| Free cash flow | -$48.9M | -$98.9M | -$167.0M | -$200.3M | -$254.5M |
| Capital expenditures | $3.0M | $3.7M | $10.7M | $16.3M | $61.7M |
| Share-based compensation | $51.5M | $53.6M | $62.9M | $55.5M | $43.3M |
| Change in accounts receivable | $8.6M | $3.7M | -$2.0M | $22.6M | $7.4M |
| Change in inventory | $998.0K | -$5.4M | $2.8M | -$817.0K | $5.2M |
| Purchases of investments | $181.7M | $244.3M | $429.6M | $278.8M | $316.5M |
| Other financing activities | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ADPT as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 31 filers
Held by These Filers76.1%
Shares Outstanding159,855,257
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $643.4M | 18.76% | +0.0% | 2026-08-14 |
| BlackRock, Inc. | 15,139,159 | $324.7M | 9.47% | +13.8% | 2026-08-07 |
| VANGUARD CAPITAL MANAGEMENT LLC | 6,403,587 | $137.4M | 4.01% | +5.1% | 2026-06-30 |
| WELLINGTON MANAGEMENT GROUP LLP | 5,911,366 | $126.8M | 3.70% | +53.2% | 2026-08-14 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5,476,231 | $117.5M | 3.43% | +21.9% | 2026-06-30 |
| D. E. Shaw & Co., Inc. | 4,625,859 | $99.2M | 2.89% | +135.3% | 2026-08-14 |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 4,267,645 | $91.5M | 2.67% | -21.5% | 2026-08-12 |
| GEODE CAPITAL MANAGEMENT, LLC | 3,641,837 | $78.1M | 2.28% | +0.2% | 2026-08-12 |
| State Street Corp | 3,458,388 | $74.2M | 2.16% | +7.2% | 2026-08-07 |
| Invesco Ltd. | 3,094,011 | $66.4M | 1.94% | -30.5% | 2026-08-13 |
| Goldman Sachs Group Inc | 2,984,227 | $64.0M | 1.87% | -8.0% | 2026-08-14 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2,665,308 | $57.2K | 1.67% | +70.2% | 2026-08-14 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 2,527,703 | $54.2M | 1.58% | +44.4% | 2026-08-14 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 2,524,620 | $54.2M | 1.58% | +26.5% | 2026-08-13 |
| LORD, ABBETT & CO. LLC | 2,474,814 | $53.1K | 1.55% | -30.0% | 2026-08-13 |
| Nuveen, LLC | 2,366,155 | $50.8M | 1.48% | +81.4% | 2026-08-11 |
| BNP Paribas Asset Management Holding S.A. | 2,182,326 | $46.8M | 1.37% | -18.8% | 2026-08-12 |
| FRED ALGER MANAGEMENT, LLC | 2,092,284 | $44.9M | 1.31% | +1.4% | 2026-08-14 |
| ARK Investment Management LLC | 2,090,306 | $44.8M | 1.31% | -0.1% | 2026-08-14 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 1,889,188 | $40.5M | 1.18% | +0.4% | 2026-08-14 |
| Aristotle Atlantic Partners, LLC | 1,838,513 | $39.4M | 1.15% | +7.2% | 2026-08-14 |
| T. Rowe Price Investment Management, Inc. | 1,779,651 | $38.2K | 1.11% | +93.6% | 2026-08-14 |
| Bank Of America Corp /De/ | 1,730,044 | $37.1M | 1.08% | +40.9% | 2026-08-14 |
| JANE STREET GROUP, LLC | 1,590,513 | $34.1M | 0.99% | +133.2% | 2026-08-14 |
| Northern Trust Corp | 1,507,351 | $32.3M | 0.94% | +8.3% | 2026-08-12 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-06-15 to 2026-10-16
Recent transactions
- Insiders have net sold 2,476,454 shares over the last 182 days, across 0 purchases and 54 sales.
- Most recent: RUBINSTEIN JULIE (President and COO) — Option exercise of 11,881 shares on 2026-10-16.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)2,476,454 sh(54 txns)
Net Shares-2,476,454
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| RUBINSTEIN JULIE | President and COO | Option exercise | 2026-10-16 | 11,881 |
| BOBULSKY SUSAN | Chief Commercial Officer, MRD | Open market sale | 2026-10-06 | 6,444 |
| LO FRANCIS | Chief People Officer | Option exercise | 2026-10-01 | 8,038 |
| OWEN KATEY EINTERZ | Director | Gift | 2026-08-31 | 12,539 |
| HERSHBERG ROBERT | Director | Option exercise | 2026-08-18 | 15,000 |
| ROBINS CHAD M | CEO and Chairman | Option exercise | 2026-08-18 | 278,676 |
| NEUPERT PETER M | Director | Option exercise | 2026-08-17 | 15,000 |
| ROBINS HARLAN S | Chief Scientific Officer | Option exercise | 2026-07-21 | 284,800 |
| BENZENO SHARON | Chief Commercial Ofc Imm Med | Option exercise | 2026-06-29 | 1,837 |
| GRIFFIN MICHELLE RENEE | Director | Option exercise | 2026-06-25 | 52,084 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-16 | RUBINSTEIN JULIE | President and COO | Option exercise | 11,881 | $12.14 |
| 2026-10-16 | RUBINSTEIN JULIE | President and COO | Open market sale | 11,581 | $24.21 |
| 2026-10-16 | RUBINSTEIN JULIE | President and COO | Open market sale | 300 | $25.45 |
| 2026-10-15 | RUBINSTEIN JULIE | President and COO | Option exercise | 11,881 | $12.14 |
| 2026-10-15 | RUBINSTEIN JULIE | President and COO | Open market sale | 11,881 | $25.61 |
| 2026-10-14 | RUBINSTEIN JULIE | President and COO | Option exercise | 11,881 | $12.14 |
| 2026-10-14 | RUBINSTEIN JULIE | President and COO | Open market sale | 6,781 | $25.57 |
| 2026-10-14 | RUBINSTEIN JULIE | President and COO | Open market sale | 5,100 | $25.82 |
| 2026-10-13 | RUBINSTEIN JULIE | President and COO | Option exercise | 11,881 | $12.14 |
| 2026-10-13 | RUBINSTEIN JULIE | President and COO | Open market sale | 11,881 | $25.50 |
| 2026-10-12 | RUBINSTEIN JULIE | President and COO | Option exercise | 11,881 | $12.14 |
| 2026-10-12 | RUBINSTEIN JULIE | President and COO | Open market sale | 9,181 | $25.35 |
| 2026-10-12 | RUBINSTEIN JULIE | President and COO | Open market sale | 2,700 | $26.07 |
| 2026-10-09 | RUBINSTEIN JULIE | President and COO | Option exercise | 11,881 | $12.14 |
| 2026-10-09 | RUBINSTEIN JULIE | President and COO | Open market sale | 11,881 | $26.41 |
| 2026-10-08 | RUBINSTEIN JULIE | President and COO | Option exercise | 11,881 | $12.14 |
| 2026-10-08 | RUBINSTEIN JULIE | President and COO | Open market sale | 11,881 | $25.66 |
| 2026-10-07 | RUBINSTEIN JULIE | President and COO | Option exercise | 11,881 | $12.14 |
| 2026-10-07 | RUBINSTEIN JULIE | President and COO | Open market sale | 11,881 | $26.40 |
| 2026-10-06 | RUBINSTEIN JULIE | President and COO | Option exercise | 11,881 | $12.14 |
| 2026-10-06 | RUBINSTEIN JULIE | President and COO | Open market sale | 9,381 | $27.36 |
| 2026-10-06 | RUBINSTEIN JULIE | President and COO | Open market sale | 1,100 | $28.21 |
| 2026-10-06 | RUBINSTEIN JULIE | President and COO | Open market sale | 901 | $29.71 |
| 2026-10-06 | RUBINSTEIN JULIE | President and COO | Open market sale | 499 | $30.53 |
| 2026-10-06 | BOBULSKY SUSAN | Chief Commercial Officer, MRD | Open market sale | 6,444 | $30.00 |
| 2026-10-05 | RUBINSTEIN JULIE | President and COO | Option exercise | 11,881 | $12.14 |
| 2026-10-05 | RUBINSTEIN JULIE | President and COO | Open market sale | 6,699 | $28.82 |
| 2026-10-05 | RUBINSTEIN JULIE | President and COO | Open market sale | 5,182 | $29.67 |
| 2026-10-02 | RUBINSTEIN JULIE | President and COO | Option exercise | 11,881 | $12.14 |
| 2026-10-02 | RUBINSTEIN JULIE | President and COO | Open market sale | 11,881 | $28.13 |
| 2026-10-01 | RUBINSTEIN JULIE | President and COO | Option exercise | 11,881 | $12.14 |
| 2026-10-01 | RUBINSTEIN JULIE | President and COO | Open market sale | 6,081 | $27.57 |
| 2026-10-01 | RUBINSTEIN JULIE | President and COO | Open market sale | 5,800 | $28.56 |
| 2026-10-01 | LO FRANCIS | Chief People Officer | Option exercise | 8,038 | $8.46 |
| 2026-10-01 | LO FRANCIS | Chief People Officer | Option exercise | 9,377 | $3.99 |
| 2026-10-01 | LO FRANCIS | Chief People Officer | Option exercise | 9,377 | $8.12 |
| 2026-10-01 | LO FRANCIS | Chief People Officer | Open market sale | 8,094 | $27.52 |
| 2026-10-01 | LO FRANCIS | Chief People Officer | Open market sale | 18,698 | $28.61 |
| 2026-09-16 | LO FRANCIS | Chief People Officer | Option exercise | 53,091 | $12.14 |
| 2026-09-16 | LO FRANCIS | Chief People Officer | Option exercise | 13,398 | $8.46 |
| 2026-09-16 | LO FRANCIS | Chief People Officer | Option exercise | 15,629 | $3.99 |
| 2026-09-16 | LO FRANCIS | Chief People Officer | Option exercise | 23,442 | $8.12 |
| 2026-09-16 | LO FRANCIS | Chief People Officer | Open market sale | 107,537 | $28.02 |
| 2026-09-16 | LO FRANCIS | Chief People Officer | Open market sale | 7,869 | $28.57 |
| 2026-09-15 | BOBULSKY SUSAN | Chief Commercial Officer, MRD | Open market sale | 1,195 | $27.00 |
| 2026-08-31 | OWEN KATEY EINTERZ | Director | Gift | 12,539 | — |
| 2026-08-26 | OWEN KATEY EINTERZ | Director | Open market sale | 9,615 | $26.00 |
| 2026-08-18 | HERSHBERG ROBERT | Director | Option exercise | 15,000 | $6.32 |
| 2026-08-18 | HERSHBERG ROBERT | Director | Open market sale | 15,000 | $24.39 |
| 2026-08-18 | HERSHBERG ROBERT | Director | Open market sale | 15,664 | $24.41 |
| 2026-08-18 | ROBINS CHAD M | CEO and Chairman | Option exercise | 278,676 | $6.55 |
| 2026-08-18 | ROBINS CHAD M | CEO and Chairman | Open market sale | 278,472 | $24.48 |
| 2026-08-18 | ROBINS CHAD M | CEO and Chairman | Open market sale | 204 | $25.14 |
| 2026-08-17 | ROBINS CHAD M | CEO and Chairman | Option exercise | 321,324 | $6.55 |
| 2026-08-17 | ROBINS CHAD M | CEO and Chairman | Open market sale | 318,799 | $25.08 |
| 2026-08-17 | ROBINS CHAD M | CEO and Chairman | Open market sale | 2,525 | $25.57 |
| 2026-08-17 | NEUPERT PETER M | Director | Option exercise | 15,000 | $6.32 |
| 2026-08-17 | NEUPERT PETER M | Director | Open market sale | 15,000 | $25.23 |
| 2026-08-17 | NEUPERT PETER M | Director | Open market sale | 40,000 | $25.10 |
| 2026-08-17 | NEUPERT PETER M | Director | Open market sale | 69,690 | $25.16 |
Showing the most recent 60 transactions.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 04:20 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-21 | 4 | 2026-10-19 | View on SEC.gov → |
| 2026-10-16 | 4 | 2026-10-14 | View on SEC.gov → |
| 2026-10-13 | 4 | 2026-10-09 | View on SEC.gov → |
| 2026-10-08 | 4 | 2026-10-06 | View on SEC.gov → |
| 2026-10-08 | 4 | 2026-10-06 | View on SEC.gov → |
| 2026-10-05 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-10-05 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-09-18 | 4 | 2026-09-16 | View on SEC.gov → |
| 2026-09-17 | 4 | 2026-09-15 | View on SEC.gov → |
| 2026-09-02 | 4 | 2026-08-31 | View on SEC.gov → |
| 2026-08-28 | 4 | 2026-08-26 | View on SEC.gov → |
| 2026-08-20 | 4 | 2026-08-18 | View on SEC.gov → |
Recent news
Headlines about ADPT (Adaptive Biotechnologies Corporation). Links open the publisher — we don’t host full articles.
-
Is Adaptive Biotechnologies Corp (ADPT) Overvalued After 3.7% Ra
GuruFocus · 2026-10-21 -
Adaptive Biotechnologies president and coo Julie Rubinstein sells $879,088 in shares
Investing.com Australia · 2026-10-21 -
Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells 11,881 Shares of Company Stock
MarketBeat · 2026-10-21 -
Adaptive Biotechnologies (NASDAQ:ADPT) COO Julie Rubinstein Sells 11,881 Shares of Company Stock
MarketBeat · 2026-10-21 -
Adaptive Biotechnologies' COO Julie Rubinstein Sells 35,643 Shares via 10b5-1 Plan from Oct 19-21, 2026
Kalkine Media · 2026-10-21 -
COO exercises options and sells 35,643 shares in Adaptive Biotechnologies (ADPT).
Stock Titan · 2026-10-21 -
Should You Be Worried About Tempus AI Stock?
Yahoo · 2026-10-20 -
Is Adaptive Biotechnologies (ADPT) Cheap After Its 16% Pullback?
Simply Wall Street · 2026-10-19
No headlines in this category right now — try “All”.